Dr. Smith Discusses CD19 CAR T-Cell Therapy in B-ALL

Eric Smith, MD, PhD
Published: Sunday, Jun 25, 2017



Eric Smith, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses CD19 (19-28Z) chimeric antigen receptor (CAR) T-cell therapy in B-cell acute lymphoblastic leukemia (B-ALL).

In a study of adult patients with relapsed/refractory B-ALL, investigators aimed to identify patients who would benefit from 19-28z CAR T-cell therapy, measured by durable long-term survival and reduced toxicities.

Results showed that the complete remission rate was 85% in this typically poor-prognosis setting.
 


Eric Smith, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses CD19 (19-28Z) chimeric antigen receptor (CAR) T-cell therapy in B-cell acute lymphoblastic leukemia (B-ALL).

In a study of adult patients with relapsed/refractory B-ALL, investigators aimed to identify patients who would benefit from 19-28z CAR T-cell therapy, measured by durable long-term survival and reduced toxicities.

Results showed that the complete remission rate was 85% in this typically poor-prognosis setting.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication
x